HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,460 | +5.9% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $10,821 | -5.6% | 300 | 0.0% | 0.00% | – |
| Q1 2023 | $11,457 | -84.5% | 300 | -76.9% | 0.00% | -100.0% |
| Q4 2022 | $73,970 | +45.0% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $51,000 | -10.5% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $57,000 | +307.1% | 1,300 | +271.4% | 0.00% | – |
| Q3 2021 | $14,000 | -12.5% | 350 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | -100.0% | 350 | -79.4% | 0.00% | -100.0% |
| Q1 2021 | $70,874,000 | +472393.3% | 1,700 | +385.7% | 0.00% | – |
| Q4 2020 | $15,000 | -64.3% | 350 | -85.4% | 0.00% | -100.0% |
| Q4 2019 | $42,000 | +13.5% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $37,000 | -24.5% | 2,400 | -16.5% | 0.00% | -50.0% |
| Q2 2019 | $49,000 | -14.0% | 2,875 | -8.1% | 0.00% | -33.3% |
| Q3 2018 | $57,000 | +7.5% | 3,130 | -0.3% | 0.00% | 0.0% |
| Q2 2018 | $53,000 | – | 3,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |